Loading...
Loading...
CNTA| Name | Value |
|---|---|
| Revenues | 15.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 15.0M |
| Operating Expense | 45.8M |
| Operating I/L | -30.8M |
| Other Income/Expense | 6.0M |
| Interest Income | 7.9M |
| Pretax | -24.7M |
| Income Tax Expense | 1.4M |
| Net Income/Loss | -26.1M |
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company focused on discovering, developing, and delivering medicines to patients. The company's registrational pipeline products include Lixivaptan for autosomal dominant polycystic kidney disease and SerpinPC for hemophilia A and B. Additionally, Centessa has emerging pipeline products under clinical proof of concept stage, such as PD-L1xCD47 and PD-L1xCD3 LockBody, ZF874 for alpha-1-antitrypsin deficiency, MGX292 for Pulmonary Arterial Hypertension, and OX2R Agonists for Narcolepsy Type 1. The company also has exploratory pipeline products including anti-LIGHT antibody CBS001 and humanized mAb CBS004 for autoimmune diseases.
